C12Y 503/03012
L-dopachrome isomerase
Official title: L-Dopachrome isomerase (5.3.3.12)
C12Y503/03012 (L-dopachrome isomerase) appears on 13 US grants and 24 published applications in this corpus.
Search patents in C12Y- Granted patents
- 13
- Published applications
- 24
- Assignees
- 16
- Inventors
- 37
- Latest grant
- 5 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 1 | 1 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 0 | 1 |
| 2009 | 0 | 2 |
| 2010 | 1 | 0 |
| 2011 | 0 | 1 |
| 2012 | 0 | 1 |
| 2013 | 1 | 0 |
| 2014 | 1 | 3 |
| 2015 | 1 | 3 |
| 2016 | 2 | 2 |
| 2017 | 0 | 1 |
| 2018 | 2 | 3 |
| 2019 | 1 | 1 |
| 2020 | 0 | 0 |
| 2021 | 2 | 1 |
| 2022 | 0 | 0 |
| 2023 | 0 | 2 |
| 2024 | 0 | 0 |
| 2025 | 0 | 0 |
| 2026 | 1 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Nucleic acid molecules5 May 2026US 12,618,060 B2CureVac AG
- MHC-independent tumor-associated antigens27 Apr 2021US 10,987,413 B2BioNTech RNA Pharmaceuticals GmbH
- Nucleic acid molecules27 Apr 2021US 10,988,754 B2Cure Vac SE
- Use of liposomes in a carrier comprising a continuous hydrophobic phase as a vehicle for cancer treatment30 Apr 2019US 10,272,042 B2Immunovaccine Technologies Inc.
- Use of liposomes in a carrier comprising a continuous hydrophobic phase as a vehicle for cancer treatment27 Mar 2018US 9,925,142 B2Immunovaccine Technologies Inc.
- Nucleic acid molecules23 Jul 2026US 2026/0209739 A1CureVac AG
- Hypoimmunogenic Cells and Methods and Compositions for Their Production23 Nov 2023US 2023/0374448 A1Rxcell Inc.
- Metabolite-based polymers, microparticles, and nanoparticles for immunotherapy and methods of treating a disease or disorder23 Feb 2023US 2023/0058160 A1
- Novel nucleic acid molecules1 Jul 2021US 2021/0198649 A1CureVac AG
- Novel nucleic acid molecules7 Feb 2019US 2019/0040378 A1Cure Vac SE
Most cited
By later US patents
- Nucleic acid molecules46US 10,988,754 B2Cure Vac SE · 2021
- Use of liposomes in a carrier comprising a continuous hydrophobic phase as a vehicle for cancer treatment32US 10,272,042 B2Immunovaccine Technologies Inc. · 2019
- Treatment, diagnosis and evaluation of anti-cancer therapy resistance in melanoma17US 6,573,050 B1Sunnybrook and Women's College Health Sciences Centre · 2003
- Use of liposomes in a carrier comprising a continuous hydrophobic phase as a vehicle for cancer treatment3US 9,925,142 B2Immunovaccine Technologies Inc. · 2018
- Method of inhibiting binding or activity of MIF by administering a MIF antagonist2US 8,617,822 B2Baxter Healthcare S. A. · 2013